Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 194864, 21 pages
http://dx.doi.org/10.1155/2015/194864
Review Article

Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives

1Interdisciplinary Department of Medicine, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
2Research Center of Systemic Autoimmune and Autoinflammatory Diseases, University of Siena, Viale Bracci 1, 53100 Siena, Italy
3Institute of Pediatrics, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy

Received 22 October 2014; Accepted 25 December 2014

Academic Editor: Pham My-Chan Dang

Copyright © 2015 Giuseppe Lopalco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. McGonagle and M. F. McDermott, “A proposed classification of the immunological diseases,” PLoS Medicine, vol. 3, no. 8, article e297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Touitou and I. Koné-Paut, “Autoinflammatory diseases,” Best Practice and Research: Clinical Rheumatology, vol. 22, no. 5, pp. 811–829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Rigante, “The fresco of autoinflammatory diseases from the pediatric perspective,” Autoimmunity Reviews, vol. 11, no. 5, pp. 348–356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Cantarini, O. M. Lucherini, F. Iacoponi et al., “Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 4, pp. 1133–1141, 2010. View at Google Scholar · View at Scopus
  5. L. Cantarini, D. Rigante, M. G. Brizi et al., “Clinical and biochemical landmarks in systemic autoinflammatory diseases,” Annals of Medicine, vol. 44, no. 7, pp. 664–673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Cantarini, F. Iacoponi, O. M. Lucherini et al., “Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults,” International Journal of Immunopathology and Pharmacology, vol. 24, no. 3, pp. 695–702, 2011. View at Google Scholar · View at Scopus
  7. I. Muscari, F. Iacoponi, L. Cantarini et al., “The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature,” Autoimmunity Reviews, vol. 12, no. 1, pp. 10–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Cantarini, A. Vitale, O. M. Lucherini et al., “Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined,” Reumatismo, vol. 65, no. 2, pp. 55–62, 2013. View at Google Scholar · View at Scopus
  9. D. Rigante, A. Vitale, O. M. Lucherini, and L. Cantarini, “The hereditary autoinflammatory disorders uncovered,” Autoimmunity Reviews, vol. 13, no. 9, pp. 892–900, 2014. View at Publisher · View at Google Scholar
  10. D. Rigante, G. Lopalco, A. Vitale et al., “Untangling the web of systemic autoinflammatory diseases,” Mediators of Inflammation, vol. 2014, Article ID 948154, 15 pages, 2014. View at Publisher · View at Google Scholar
  11. L. Cantarini, A. Vitale, O. M. Lucherini et al., “The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy,” Clinical Rheumatology, 2014. View at Publisher · View at Google Scholar
  12. F. Caso, D. Rigante, A. Vitale et al., “Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues,” International Journal of Rheumatology, vol. 2013, Article ID 513782, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Caso, L. Cantarini, O. M. Lucherini et al., “Working the endless puzzle of hereditary autoinflammatory disorders,” Modern Rheumatology, vol. 24, no. 3, pp. 381–389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Vitale, D. Rigante, M. C. Maggio et al., “Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series,” Clinical and Experimental Rheumatology, vol. 31, no. 3, supplement 77, pp. 155–156, 2013. View at Google Scholar · View at Scopus
  15. D. Rigante, I. la Torraca, V. Ansuini, A. Compagnone, A. Sallì, and A. Stabile, “The multi-face expression of familial mediterranean fever in the child,” European Review for Medical and Pharmacological Sciences, vol. 10, no. 4, pp. 163–171, 2006. View at Google Scholar · View at Scopus
  16. D. Rigante, B. Frediani, M. Galeazzi, and L. Cantarini, “From the mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases,” BioMed Research International, vol. 2013, Article ID 485103, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Lane, J. M. Loeffler, D. M. Rowczenio et al., “AA amyloidosis complicating the hereditary periodic fever syndromes,” Arthritis & Rheumatism, vol. 65, no. 4, pp. 1116–1121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Rigante, V. Ansuini, M. Caldarelli, B. Bertoni, I. la Torraca, and A. Stabile, “Hydrocephalus in CINCA syndrome treated with anakinra,” Child's Nervous System, vol. 22, no. 4, pp. 334–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Vitale, D. Rigante, O. M. Lucherini et al., “Biological treatments: new weapons in the management of monogenic autoinflammatory disorders,” Mediators of Inflammation, vol. 2013, Article ID 939847, 16 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Ter Haar, H. Lachmann, S. Özen et al., “Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review,” Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 678–685, 2013. View at Publisher · View at Google Scholar
  21. L. Cantarini, O. M. Lucherini, B. Frediani et al., “Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes,” International Journal of Immunopathology and Pharmacology, vol. 24, no. 4, pp. 827–836, 2011. View at Google Scholar · View at Scopus
  22. S. Ozen, E. Demirkaya, G. Amaryan et al., “Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children,” Annals of the Rheumatic Diseases, vol. 73, pp. 662–667, 2014. View at Google Scholar
  23. L. Cantarini, P. L. Capecchi, O. M. Lucherini, F. Laghi Pasini, and M. Galeazzi, “Familial Mediterranean fever diagnosed in an elderly patient,” Clinical and Experimental Rheumatology, vol. 28, no. 4, supplement 6, p. S91, 2010. View at Google Scholar · View at Scopus
  24. D. Rigante, G. Lopalco, A. Vitale et al., “Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome,” Clinical Rheumatology, vol. 33, no. 9, pp. 1197–1207, 2014. View at Publisher · View at Google Scholar
  25. H. J. Lachmann, R. Papa, K. Gerhold et al., “The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry,” Annals of the Rheumatic Diseases, vol. 73, no. 12, pp. 2160–2167, 2014. View at Publisher · View at Google Scholar
  26. F. Magnotti, A. Vitale, D. Rigante et al., “The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review,” Clinical and Experimental Rheumatology, vol. 31, supplement 77, no. 3, pp. S141–S149, 2013. View at Google Scholar · View at Scopus
  27. L. Cantarini, D. Rigante, O. M. Lucherini et al., “Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 3, pp. 701–707, 2010. View at Google Scholar · View at Scopus
  28. L. Cantarini, O. M. Lucherini, R. Cimaz, C. T. Baldari, F. Laghi Pasini, and M. Galeazzi, “Sacroileitis and pericarditis: Atypical presentation of tumour necrosis factor receptor-associated periodic syndrome and response to etanercept therapy,” Clinical and Experimental Rheumatology, vol. 28, no. 2, pp. 290–291, 2010. View at Google Scholar · View at Scopus
  29. L. Cantarini, O. M. Lucherini, R. Cimaz et al., “Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series,” Rheumatology International, vol. 32, no. 12, pp. 4015–4018, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Cantarini, O. M. Lucherini, M. Galeazzi et al., “Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment,” Clinical and Experimental Rheumatology, vol. 27, no. 5, pp. 890–891, 2009. View at Google Scholar · View at Scopus
  31. L. Cantarini, A. Vitale, F. Magnotti et al., “Weekly oral alendronate in mevalonate kinase deficiency,” Orphanet Journal of Rare Diseases, vol. 8, no. 1, article 196, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. R. van der Burgh, N. M. ter Haar, M. L. Boes, and J. Frenkel, “Mevalonate kinase deficiency, a metabolic autoinflammatory disease,” Clinical Immunology, vol. 147, no. 3, pp. 197–206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Levy, L. Gérard, J. Kuemmerle-Deschner et al., “Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry,” Annals of the Rheumatic Diseases, 2014. View at Publisher · View at Google Scholar
  34. A. Vitale, O. M. Lucherini, M. Galeazzi, B. Frediani, and L. Cantarini, “Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series,” Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 943–946, 2012. View at Google Scholar · View at Scopus
  35. E. J. Smith, F. Allantaz, L. Bennett et al., “Clinical, molecular, and genetic characteristics of PAPA syndrome: a review,” Current Genomics, vol. 11, no. 7, pp. 519–527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. P. Demidowich, A. F. Freeman, D. B. Kuhns et al., “Genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne),” Arthritis and Rheumatism, vol. 64, no. 6, pp. 2022–2027, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Tallon and M. Corkill, “Peculiarities of PAPA syndrome,” Rheumatology, vol. 45, no. 9, pp. 1140–1143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Herlin, B. Fiirgaard, M. Bjerre et al., “Efficacy of anti-IL-1 treatment in Majeed syndrome,” Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 410–413, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. H. I. El-Shanti and P. J. Ferguson, “Chronic recurrent multifocal osteomyelitis: a concise review and genetic update,” Clinical Orthopaedics and Related Research, vol. 462, pp. 11–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. J. Ferguson and H. I. El-Shanti, “Autoinflammatory bone disorders,” Current Opinion in Rheumatology, vol. 19, no. 5, pp. 492–498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Caso, L. Costa, D. Rigante et al., “Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis,” Autoimmunity Reviews, vol. 13, no. 12, pp. 1220–1229, 2014. View at Publisher · View at Google Scholar
  42. F. la Torre, G. Lapadula, L. Cantarini, O. M. Lucherini, and F. Iannone, “Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature,” Clinical Rheumatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Sfriso, F. Caso, S. Tognon, P. Galozzi, A. Gava, and L. Punzi, “Blau syndrome, clinical and genetic aspects,” Autoimmunity Reviews, vol. 12, no. 1, pp. 44–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. K. S. Stojanovic, Y. Delmas, P. U. Torres et al., “Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure,” Nephrology Dialysis Transplantation, vol. 27, no. 5, pp. 1898–1901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Moser, G. Pohl, I. Haslinger et al., “Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 676–678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. U. Meinzer, P. Quartier, J.-F. Alexandra, V. Hentgen, F. Retornaz, and I. Koné-Paut, “Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature,” Seminars in Arthritis and Rheumatism, vol. 41, no. 2, pp. 265–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Calligaris, F. Marchetti, A. Tommasini, and A. Ventura, “The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever,” European Journal of Pediatrics, vol. 167, no. 6, pp. 695–696, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. I. Mitroulis, V. P. Papadopoulos, T. Konstantinidis, and K. Ritis, “Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient,” The Netherlands Journal of Medicine, vol. 66, no. 11, pp. 489–491, 2008. View at Google Scholar · View at Scopus
  49. A. D. Petropoulou, M. Robin, G. Socié, and L. Galicier, “Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra,” Transplantation, vol. 90, no. 1, pp. 102–103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Soriano, E. Verecchia, A. Afeltra, R. Landolfi, and R. Manna, “IL-1β biological treatment of familial mediterranean fever,” Clinical Reviews in Allergy & Immunology, vol. 45, no. 1, pp. 117–130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Estublier, K. S. Stojanovic, J.-F. Bergerot, C. Broussolle, and P. Sève, “Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra,” Joint Bone Spine, vol. 80, no. 6, pp. 645–649, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Alpay, A. Şumnu, Y. ÇalIśkan, H. Yazıcı, A. Türkmen, and A. Gül, “Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever,” Rheumatology International, vol. 32, no. 10, pp. 3277–3279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Belkhir, L. Moulonguet-Doleris, E. Hachulla, J. Prinseau, A. Baglin, and T. Hanslik, “Treatment of familial mediterranean fever with anakinra,” Annals of Internal Medicine, vol. 146, no. 11, pp. 825–826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Gattringer, H. Lagler, K. B. Gattringer et al., “Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky,” European Journal of Clinical Investigation, vol. 37, no. 11, pp. 912–914, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. L. M. Kuijk, A. M. A. P. Govers, W. J. D. Hofhuis, and J. Frenkel, “Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra,” Annals of the Rheumatic Diseases, vol. 66, no. 11, pp. 1545–1546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Özen, Y. Bilginer, N. A. Ayaz, and M. Calguneri, “Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine,” The Journal of Rheumatology, vol. 38, no. 3, pp. 516–518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Roldan, A. M. Ruiz, M. D. Miranda, and E. Collantes, “Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine,” Joint Bone Spine, vol. 75, no. 4, pp. 504–505, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. O. Akgul, E. Kilic, G. Kilic, and S. Ozgocmen, “Efficacy and safety of biologic treatments in familial Mediterranean fever,” The American Journal of the Medical Sciences, vol. 346, no. 2, pp. 137–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Cantarini, O. M. Lucherini, R. Cimaz, and M. Galeazzi, “Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment,” Clinical and Experimental Rheumatology, vol. 28, no. 5, article 802, 2010. View at Google Scholar · View at Scopus
  60. M. Gattorno, M. A. Pelagatti, A. Meini et al., “Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome,” Arthritis & Rheumatism, vol. 58, no. 5, pp. 1516–1520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Simon, E. J. Bodar, J. C. H. van der Hilst et al., “Beneficial response to interleukin-1 receptor antagonist in TRAPS,” The American Journal of Medicine, vol. 117, no. 3, pp. 208–210, 2004. View at Google Scholar · View at Scopus
  62. K. Sacré, B. Brihaye, O. Lidove et al., “Dramatic improvement following interleukin 1β blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-α therapy,” Journal of Rheumatology, vol. 35, no. 2, pp. 357–358, 2008. View at Google Scholar · View at Scopus
  63. M. Andrés and E. Pascual, “Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation,” Annals of the Rheumatic Diseases, vol. 72, no. 1, p. 155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. O. M. Lucherini, L. Obici, M. Ferracin et al., “First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS),” PLoS ONE, vol. 8, no. 9, Article ID e73443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Cailliez, F. Garaix, C. Rousset-Rouvière et al., “Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis,” Journal of Inherited Metabolic Disease, vol. 29, no. 6, p. 763, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Rigante, V. Ansuini, B. Bertoni et al., “Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome,” Rheumatology International, vol. 27, no. 1, pp. 97–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Lequerré, O. Vittecoq, S. Pouplin et al., “Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra,” Rheumatology, vol. 46, no. 12, pp. 1860–1862, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Galeotti, U. Meinzer, P. Quartier et al., “Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency,” Rheumatology, vol. 51, no. 10, pp. 1855–1859, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. E. J. Bodar, L. M. Kuijk, J. P. H. Drenth, J. W. M. van der Meer, A. Simon, and J. Frenkel, “On-demand anakinra treatment is effective in mevalonate kinase deficiency,” Annals of the Rheumatic Diseases, vol. 70, no. 12, pp. 2155–2158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. E. J. Bodar, J. C. H. van der Hilst, J. P. H. Drenth, J. W. M. van der Meer, and A. Simon, “Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model,” Netherlands Journal of Medicine, vol. 63, no. 7, pp. 260–264, 2005. View at Google Scholar · View at Scopus
  71. A. R. Gomez, M. L. Couce, J. Garcia-Villoria et al., “Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency,” Pediatrics, vol. 129, no. 2, pp. e535–e539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. H. M. Shendi, D. Walsh, and J. D. M. Edgar, “Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome,” Rheumatology International, vol. 32, no. 1, pp. 249–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. C. B. Teoh, S. Sharma, A. Hogan, R. Lee, A. V. Ramanan, and A. D. Dick, “Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome,” British Journal of Ophthalmology, vol. 91, no. 2, pp. 263–264, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. C. M. Hedrich, N. Bruck, D. Paul, M. Gahr, A. Rösen-Wolv, and G. Hahn, “‘Mutation negative’ familial cold autoinXammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies,” Rheumatology International, vol. 32, no. 9, pp. 2629–2636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Goldbach-Mansky, N. J. Dailey, S. W. Canna et al., “Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition,” The New England Journal of Medicine, vol. 355, no. 6, pp. 581–592, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Gattorno, S. Tassi, S. Carta et al., “Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations,” Arthritis & Rheumatism, vol. 56, no. 9, pp. 3138–3148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Neven, I. Marvillet, C. Terrada et al., “Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 258–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Lepore, G. Paloni, R. Caorsi et al., “Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra,” The Journal of Pediatrics, vol. 157, no. 2, pp. 310.e1–315.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Miyamae, Y. Inaba, G. Nishimura et al., “Effect of anakinra on arthropathy in CINCA/NOMID syndrome,” Pediatric Rheumatology, vol. 8, article 9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. D. J. Lovell, S. L. Bowyer, and A. M. Solinger, “Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease,” Arthritis & Rheumatism, vol. 52, no. 4, pp. 1283–1286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Aubert, M. Suárez-Fariñas, H. Mitsui et al., “Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β,” PLoS ONE, vol. 7, no. 11, Article ID e49408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. J. E. Balow Jr., J. G. Ryan, J. J. Chae et al., “Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 1064–1070, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. C. H. Sibley, N. Plass, J. Snow et al., “Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes,” Arthritis & Rheumatism, vol. 64, no. 7, pp. 2375–2386, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. P. N. Hawkins, H. J. Lachmann, and M. F. McDermott, “Interleukin-1-receptor antagonist in the Muckle-Wells syndrome,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2583–2584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Rynne, C. Maclean, A. Bybee, M. F. McDermott, and P. Emery, “Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 533–534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. B. T. Stew, S. J. C. Fishpool, D. Owens, and S. Quine, “Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss,” B-ENT, vol. 9, no. 2, pp. 161–163, 2013. View at Google Scholar · View at Scopus
  87. R. A. Sabroe, C. A. Stokes, L. C. Parker, K. Higgins, L. R. Prince, and I. Sabroe, “Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra,” Clinical and Experimental Dermatology, vol. 38, no. 8, pp. 874–877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Enríquez, A. E. Sirvent, S. Padilla et al., “Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome,” Renal Failure, vol. 35, no. 5, pp. 738–741, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. J. B. Kuemmerle-Deschner, P. N. Tyrrell, I. Koetter et al., “Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome,” Arthritis & Rheumatism, vol. 63, no. 3, pp. 840–849, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. P. N. Hawkins, H. J. Lachmann, E. Aganna, and M. F. McDermott, “Spectrum of clinical Features in Muckle-Wells syndrome and response to anakinra,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 607–612, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. S. K. Metyas and H. M. Hoffman, “Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease,” Journal of Rheumatology, vol. 33, no. 10, pp. 2085–2087, 2006. View at Google Scholar · View at Scopus
  92. H. M. Hoffman, S. Rosengren, D. L. Boyle et al., “Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist,” The Lancet, vol. 364, no. 9447, pp. 1779–1785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. J. B. Kuemmerle-Deschner, H. Wittkowski, P. N. Tyrrell et al., “Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens,” Arthritis Research and Therapy, vol. 15, no. 3, article R64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. J. B. Kuemmerle-Deschner, P. Lohse, I. Koetter et al., “NLRP3 E311K mutation in a large family with Muckle-Wells syndrome—description of a heterogeneous phenotype and response to treatment,” Arthritis Research and Therapy, vol. 13, no. 6, article R196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Pazyar, A. Feily, and R. Yaghoobi, “An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases,” Current Clinical Pharmacology, vol. 7, no. 4, pp. 271–275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Braun-Falco, O. Kovnerystyy, P. Lohse, and T. Ruzicka, “Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome,” Journal of the American Academy of Dermatology, vol. 66, no. 3, pp. 409–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Brenner, T. Ruzicka, G. Plewig, P. Thomas, and P. Herzer, “Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra,” British Journal of Dermatology, vol. 161, no. 5, pp. 1199–1201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. M. P. Dierselhuis, J. Frenkel, N. M. Wulffraat, and J. J. Boelens, “Anakinra for flares of pyogenic arthritis in PAPA syndrome,” Rheumatology, vol. 44, no. 3, pp. 406–408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. M. A. Schellevis, M. Stoffels, E. P. A. H. Hoppenreijs, E. Bodar, A. Simon, and J. W. M. van der Meer, “Variable expression and treatment of PAPA syndrome,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 1168–1170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. N. G. Shoham, M. Centola, E. Mansfield et al., “Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13501–13506, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Punzi, A. Gava, P. Galozzi, and P. Sfriso, “Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome.,” Best Practice and Research: Clinical Rheumatology, vol. 25, no. 5, pp. 703–714, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. T. M. Martin, Z. Zhang, P. Kurz et al., “The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity,” Arthritis and Rheumatism, vol. 60, no. 2, pp. 611–618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. D. O. Hacihamdioglu and S. Ozen, “Canakinumab induces remission in a patient with resistant familial Mediterranean fever,” Rheumatology, vol. 51, no. 6, Article ID kes021, p. 1041, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. I. Mitroulis, P. Skendros, A. Oikonomou, A. G. Tzioufas, and K. Ritis, “The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1347–1348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. M. G. Brizi, M. Galeazzi, O. M. Lucherini, L. Cantarini, and R. Cimaz, “Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab,” Annals of Internal Medicine, vol. 156, no. 12, pp. 907–908, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Gattorno, L. Obici, and A. Meini, “Efficacy and safety of canakinumab in patients with TNF receptor-associated periodic syndrome,” Arthritis & Rheumatism, vol. 64, article 749, 2012. View at Google Scholar
  107. G. Lopalco, D. Rigante, A. Vitale, B. Frediani, F. Iannone, and L. Cantarini, “Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate,” Clinical Rheumatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. C. H. Sibley, A. Chioato, S. Felix et al., “A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease,” Annals of the Rheumatic Diseases, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Caorsi, L. Lepore, F. Zulian et al., “The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age,” Arthritis Research and Therapy, vol. 15, article R33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. T. Imagawa, R. Nishikomori, H. Takada et al., “Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results),” Clinical and Experimental Rheumatology, vol. 31, no. 2, pp. 302–309, 2013. View at Google Scholar · View at Scopus
  111. S. M. Mueller, P. Itin, and P. Haeusermann, “Muckle-wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?” Dermatology, vol. 223, no. 2, pp. 113–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. H. J. Lachmann, I. Kone-Paut, J. B. Kuemmerle-Deschner et al., “Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2416–2425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. I. Koné-Paut, H. J. Lachmann, J. B. Kuemmerle-Deschner et al., “Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study,” Arthritis Research and Therapy, vol. 13, no. 6, article no. R202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. J. B. Kuemmerle-Deschner, E. Ramos, N. Blank et al., “Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS),” Arthritis Research and Therapy, vol. 13, article R34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. J. B. Kuemmerle-Deschner, E. Hachulla, R. Cartwright et al., “Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes,” Annals of the Rheumatic Diseases, vol. 70, no. 12, pp. 2095–2102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. R. Scarpioni, D. Rigante, L. Cantarini et al., “Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab,” Clinical Rheumatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Geusau, N. Mothes-Luksch, H. Nahavandi et al., “Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment,” JAMA Dermatology, vol. 149, no. 2, pp. 209–215, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. G. Simonini, Z. Xu, R. Caputo et al., “Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis,” Arthritis and Rheumatism, vol. 65, no. 2, pp. 513–518, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. P. J. Hashkes, S. J. Spalding, E. H. Giannini et al., “Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial,” Annals of Internal Medicine, vol. 157, no. 8, pp. 533–541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. P. J. Hashkes, S. J. Spalding, R. Hajj-Ali et al., “The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever,” BioMed Research International, vol. 2014, Article ID 854842, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. B. Huang, E. H. Giannini, D. J. Lovell, L. Ding, Y. Liu, and P. J. Hashkes, “Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early,” Contemporary Clinical Trials, vol. 38, no. 2, pp. 204–212, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. L. D. Church, S. Savic, and M. F. McDermott, “Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap),” Biologics: Targets and Therapy, vol. 2, no. 4, pp. 733–742, 2008. View at Google Scholar · View at Scopus
  123. J. Gillespie, R. Mathews, and M. F. McDermott, “Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS),” Journal of Inflammation Research, vol. 3, no. 1, pp. 1–8, 2010. View at Google Scholar · View at Scopus
  124. R. Goldbach-Mansky, S. D. Shroff, M. Wilson et al., “A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome,” Arthritis & Rheumatism, vol. 58, no. 8, pp. 2432–2442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. H. M. Hoffman, M. L. Throne, N. J. Amar et al., “Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2443–2452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. H. M. Hoffman, M. L. Throne, N. J. Amar et al., “Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study,” Clinical Therapeutics, vol. 34, no. 10, pp. 2091–2103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. H. M. Hoffman, “Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS),” Expert Opinion on Biological Therapy, vol. 9, no. 4, pp. 519–531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Kapur, M. E. Bonk, and A. Caspi, “Rilonacept (arcalyst), an interleukin-I trap for the treatment of cryopyrin-associated periodic syndromes,” Pharmacology & Therapeutics, vol. 34, no. 3, pp. 138–141, 2009. View at Google Scholar · View at Scopus
  129. K. T. Thomas, H. M. Feder Jr., A. R. Lawton, and K. M. Edwards, “Periodic fever syndrome in children,” The Journal of Pediatrics, vol. 135, no. 1, pp. 15–21, 1999. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Padeh, N. Brezniak, D. Zemer et al., “Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome,” Journal of Pediatrics, vol. 135, no. 1, pp. 98–101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  131. D. C. Knockaert, L. J. Vanneste, and H. J. Bobbaers, “Recurrent or episodic fever of unknown origin: review of 45 cases and survey of the literature,” Medicine, vol. 72, no. 3, pp. 184–196, 1993. View at Publisher · View at Google Scholar · View at Scopus
  132. G. S. Marshall, K. M. Edwards, J. Butler, and A. R. Lawton, “Syndrome of periodic fever, pharyngitis, and aphthous stomatitis,” Journal of Pediatrics, vol. 110, no. 1, pp. 43–46, 1987. View at Publisher · View at Google Scholar · View at Scopus
  133. L. Cantarini, A. Vitale, B. Bartolomei, M. Galeazzi, and D. Rigante, “Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers,” Clinical and Experimental Rheumatology, vol. 30, no. 2, pp. 269–271, 2012. View at Google Scholar · View at Scopus
  134. J. Førsvoll, E. K. Kristoffersen, and K. Øymar, “Elevated levels of CXCL10 in the periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA) during and between febrile episodes; an indication of a persistent activation of the innate immune system,” Pediatric Rheumatology, vol. 11, article 38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. K. L. Brown, P. Wekell, V. Osla et al., “Profile of blood cells and inflammatory mediators in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome,” BMC Pediatrics, vol. 10, article 65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. D. Rigante, “The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration,” European Review for Medical and Pharmacological Sciences, vol. 14, no. 1, pp. 1–18, 2010. View at Google Scholar · View at Scopus
  137. S. Stojanov, F. Hoffmann, A. Kéry et al., “Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response,” European Cytokine Network, vol. 17, no. 2, pp. 90–97, 2006. View at Google Scholar · View at Scopus
  138. L. Kolly, N. Busso, A. von Scheven-Gete et al., “Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1β production,” Journal of Allergy and Clinical Immunology, vol. 131, no. 6, pp. 1635–1643, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. S. Stojanov, S. Lapidus, P. Chitkara et al., “Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7148–7153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. L. Cantarini, A. Vitale, M. Galeazzi, and B. Frediani, “A case of resistant adult-onset periodic fever, aphtous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra,” Clinical and Experimental Rheumatology, vol. 30, no. 4, p. 593, 2012. View at Google Scholar · View at Scopus
  141. C. Bansard, T. Lequerré, C. Derambure et al., “Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra),” Rheumatology, vol. 50, no. 2, pp. 283–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. N. J. Olsen and C. M. Stein, “New drugs for rheumatoid arthritis,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2167–2226, 2004. View at Publisher · View at Google Scholar · View at Scopus
  143. J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, “New therapies for treatment of rheumatoid arthritis,” The Lancet, vol. 370, no. 9602, pp. 1861–1874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. J. F. Camargo, P. A. Correa, J. Castiblanco, and J. M. Anaya, “Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases,” Genes and Immunity, vol. 5, no. 8, pp. 609–614, 2004. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Miyata, Y. Ohkubo, and S. Mutoh, “A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis,” Inflammation Research, vol. 54, no. 1, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. R. M. Fleischmann, J. Schechtman, R. Bennett et al., “Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial,” Arthritis & Rheumatism, vol. 48, no. 4, pp. 927–934, 2003. View at Publisher · View at Google Scholar · View at Scopus
  147. B. Bresnihan, J. M. Alvaro-Gracia, M. Cobby et al., “Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist,” Arthritis & Rheumatism, vol. 41, no. 12, pp. 2196–2204, 1998. View at Google Scholar
  148. S. B. Abramson and A. Amin, “Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage,” Rheumatology, vol. 41, no. 9, pp. 972–980, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. B. Bresnihan and M. Cobby, “Clinical and radiological effects of anakinra in patients with rheumatoid arthritis,” Rheumatology, vol. 42, supplement 2, pp. ii22–ii28, 2003. View at Google Scholar · View at Scopus
  150. J. A. Singh, R. Christensen, G. A. Wells et al., “Biologics for rheumatoid arthritis: an overview of Cochrane reviews,” São Paulo Medical Journal, vol. 128, no. 5, pp. 309–310, 2010. View at Google Scholar · View at Scopus
  151. J. Bao, T. Yue, W. Liu et al., “Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 30, no. 5, pp. 697–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. B. Bresnihan, R. D. Newmark, S. Robbins, D. P. McCabe, and H. K. Genant, “Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 43, supplement 9, article S289, 2000. View at Google Scholar
  153. G. Cunnane, A. Madigan, E. Murphy, O. FitzGerald, and B. Bresnihan, “The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis,” Rheumatology, vol. 40, no. 1, pp. 62–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  154. E. B. Devine, R. Alfonso-Cristancho, and S. D. Sullivan, “Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach,” Pharmacotherapy, vol. 31, no. 1, pp. 39–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. S.-Y. Wang, Y.-Y. Liu, H. Ye et al., “Circulating dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis,” The Journal of Rheumatology, vol. 38, no. 5, pp. 821–827, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. E. Turkstra, S.-K. Ng, and P. A. Scuffham, “A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis,” Current Medical Research and Opinion, vol. 27, no. 10, pp. 1885–1897, 2011. View at Publisher · View at Google Scholar · View at Scopus
  157. R. Nixon, N. Bansback, and A. Brennan, “The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons,” Rheumatology, vol. 46, no. 7, pp. 1140–1147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. S. B. Cohen, V. Strand, D. Aguilar, and J. J. Ofman, “Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy,” Rheumatology, vol. 43, no. 6, pp. 704–711, 2004. View at Publisher · View at Google Scholar · View at Scopus
  159. S. B. Cohen, “The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 30, no. 2, pp. 365–380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Kavanaugh, “Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis,” Advances in Therapy, vol. 23, no. 2, pp. 208–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. S. B. Cohen, J. M. Woolley, and W. W. Chan, “Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 30, no. 2, pp. 225–231, 2003. View at Google Scholar · View at Scopus
  162. S. B. Cohen, L. W. Moreland, J. J. Cush et al., “A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate,” Annals of the Rheumatic Diseases, vol. 63, no. 9, pp. 1062–1068, 2004. View at Publisher · View at Google Scholar · View at Scopus
  163. B. Bresnihan, R. Newmark, S. Robbins, and H. K. Genant, “Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-Week randomized, placebo-controlled trial,” The Journal of Rheumatology, vol. 31, no. 6, pp. 1103–1111, 2004. View at Google Scholar · View at Scopus
  164. Y. Jiang, H. K. Genant, I. Watt et al., “A multicenter, double-blind, dose-ranging, randomized, placebo-controlled studyof recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores,” Arthritis & Rheumatism, vol. 43, no. 5, pp. 1001–1009, 2000. View at Google Scholar
  165. H. K. Genant, B. Bresnihan, E. Ng, S. Robbins, R. D. Newmark, and D. McCabe, “Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 40, supplement 1, article 169, 2001. View at Google Scholar
  166. D. M. Miller, E. Ng, M. H. Schiff, S. B. Cohen, and B. Bresnihan, “Durability and rapidity of response for rheumatoid arthritis patients receiving therapy with anakinra,” Annals of the Rheumatic Diseases, vol. 60, supplement 1, p. 171, 2001. View at Google Scholar
  167. G. Gartlehner, R. A. Hansen, B. L. Jonas, P. Thieda, and K. N. Lohr, “The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis,” Journal of Rheumatology, vol. 33, no. 12, pp. 2398–2408, 2006. View at Google Scholar · View at Scopus
  168. M. Mertens and J. A. Singh, “Anakinra for rheumatoid arthritis: a systematic review,” Journal of Rheumatology, vol. 36, no. 6, pp. 1118–1125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  169. B. Blumenauer, M. Judd, A. Cranney et al., “Etanercept for the treatment of rheumatoid arthritis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004525, 2003. View at Google Scholar
  170. F. Navarro-Sarabia, R. Ariza-Ariza, B. Hernandez-Cruz, and I. Villanueva, “Adalimumab for treating rheumatoid arthritis,” The Cochrane Database of Systematic Reviews, no. 3, Article ID CD005113, 2005. View at Google Scholar
  171. R. Alten, J. Gomez-Reino, P. Durez et al., “Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study,” BMC Musculoskeletal Disorders, vol. 12, article 153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. I. Demin, B. Hamrén, O. Luttringer, G. Pillai, and T. Jung, “Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development,” Clinical Pharmacology and Therapeutics, vol. 92, no. 3, pp. 352–359, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. K. Esposito, F. Nappo, F. Giugliano et al., “Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus,” The American Journal of Clinical Nutrition, vol. 78, no. 6, pp. 1135–1140, 2003. View at Google Scholar · View at Scopus
  174. R. Stienstra, L. A. B. Joosten, T. Koenen et al., “The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity,” Cell Metabolism, vol. 12, no. 6, pp. 593–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. K. Maedler, P. Sergeev, F. Ris et al., “Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets,” The Journal of Clinical Investigation, vol. 110, no. 6, pp. 851–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  176. K. Maedler, G. A. Spinas, R. Lehmann et al., “Glucose induces β-cell apoptosis via up regulation of the Fas receptor in human islets,” Diabetes, vol. 50, no. 8, pp. 1683–1690, 2001. View at Publisher · View at Google Scholar · View at Scopus
  177. K. Maedler, A. Fontana, F. Ris et al., “FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 12, pp. 8236–8241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  178. S. L. Masters, A. Dunne, S. L. Subramanian et al., “Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes,” Nature Immunology, vol. 11, no. 10, pp. 897–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  179. M. Y. Donath, D. J. Gross, E. Cerasi, and N. Kaiser, “Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes,” Diabetes, vol. 48, no. 4, pp. 738–744, 1999. View at Publisher · View at Google Scholar · View at Scopus
  180. D. LeRoith, “β-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities,” The American Journal of Medicine, vol. 113, no. 6, supplement, pp. 3–11, 2002. View at Publisher · View at Google Scholar · View at Scopus
  181. M. Y. Donath and P. A. Halban, “Decreased β-cell mass in diabetes: significance, mechanisms and therapeutic implications,” Diabetologia, vol. 47, no. 3, pp. 581–589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  182. C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-receptor antagonist in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  183. C. M. Larsen, M. Faulenbach, A. Vaag, J. A. Ehses, M. Y. Donath, and T. Mandrup-Poulsen, “Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes,” Diabetes Care, vol. 32, no. 9, pp. 1663–1668, 2009. View at Publisher · View at Google Scholar · View at Scopus
  184. J. Hensen, C. P. Howard, V. Walter, and T. Thuren, “Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial,” Diabetes and Metabolism, vol. 39, no. 6, pp. 524–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  185. P. M. Ridker, C. P. Howard, V. Walter et al., “Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen a phase IIb randomized, placebo-controlled trial,” Circulation, vol. 126, no. 23, pp. 2739–2748, 2012. View at Publisher · View at Google Scholar · View at Scopus
  186. A. Noe, C. Howard, T. Thuren, A. Taylor, and A. Skerjanec, “Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus,” Clinical Therapeutics, vol. 36, no. 11, pp. 1625–1637, 2014. View at Publisher · View at Google Scholar
  187. C. Cavelti-Weder, R. Furrer, C. Keller et al., “Inhibition of IL-1β improves fatigue in type 2 diabetes,” Diabetes Care, vol. 34, no. 10, article e158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  188. C. Cavelti-Weder, A. Babians-Brunner, C. Keller et al., “Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes,” Diabetes Care, vol. 35, no. 8, pp. 1654–1662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  189. A. M. Owyang, K. Maedler, L. Gross et al., “XOMA 052, an anti-IL-1β monoclonal antibody, improves glucose control and β-cell function in the diet-induced obesity mouse model,” Endocrinology, vol. 151, no. 6, pp. 2515–2527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  190. M. Handa, S. Vanegas, B. A. Maddux et al., “XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes,” Obesity, vol. 21, no. 2, pp. 306–309, 2013. View at Publisher · View at Google Scholar · View at Scopus
  191. C. Selmi, “Diagnosis and classification of autoimmune uveitis,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 591–594, 2014. View at Publisher · View at Google Scholar · View at Scopus
  192. D. Lasigliè, E. Traggiai, S. Federici et al., “Role of IL-1 beta in the development of human TH17 cells: lesson from NLPR3 mutated patients,” PLoS ONE, vol. 6, no. 5, Article ID e20014, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. H. Kitamei, K. Iwabuchi, K. Namba et al., “Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-κB (NF-κB), pyrrolidine dithiocarbamate,” Journal of Leukocyte Biology, vol. 79, no. 6, pp. 1193–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  194. A. Lennikov, N. Kitaichi, K. Noda et al., “Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats,” Molecular Vision, vol. 18, pp. 2586–2597, 2012. View at Google Scholar · View at Scopus
  195. A. F. de Vos, V. N. A. Klaren, and A. Kijlstra, “Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat,” Investigative Ophthalmology & Visual Science, vol. 35, no. 11, pp. 3873–3883, 1994. View at Google Scholar · View at Scopus
  196. G. Simonini, L. Cantarini, C. Bresci, M. Lorusso, M. Galeazzi, and R. Cimaz, “Current therapeutic approaches to autoimmune chronic uveitis in children,” Autoimmunity Reviews, vol. 9, no. 10, pp. 674–683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  197. W.-K. Lim, C. Fujimoto, R. Ursea et al., “Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration,” Archives of Ophthalmology, vol. 123, no. 7, pp. 957–963, 2005. View at Publisher · View at Google Scholar · View at Scopus
  198. J. I. Aróstegui, C. Arnal, R. Merino et al., “NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort,” Arthritis and Rheumatism, vol. 56, no. 11, pp. 3805–3813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  199. A. Gül, I. Tugal-Tutkun, C. A. Dinarello et al., “Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 563–566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  200. R. Shabetai, “Editorial: Often neglected yet important: the pericardium and its diseases,” Herz, vol. 25, no. 8, pp. 717–719, 2000. View at Publisher · View at Google Scholar · View at Scopus
  201. W. C. Little and G. L. Freeman, “Pericardial disease,” Circulation, vol. 113, no. 12, pp. 1622–1632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  202. R. W. Troughton, C. R. Asher, and A. L. Klein, “Pericarditis,” The Lancet, vol. 363, no. 9410, pp. 717–727, 2004. View at Google Scholar · View at Scopus
  203. L. Cantarini, M. Imazio, M. G. Brizi et al., “Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis,” Clinical Reviews in Allergy and Immunology, vol. 44, no. 1, pp. 6–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  204. M. Imazio, “Treatment of recurrent pericarditis,” Expert Review of Cardiovascular Therapy, vol. 10, no. 9, pp. 1165–1172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  205. S. Maestroni, P. R. Di Corato, D. Cumetti et al., “Recurrent pericarditis: autoimmune or autoinflammatory?” Autoimmunity Reviews, vol. 12, no. 1, pp. 60–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  206. C. A. Dinarello and J. W. M. van der Meer, “Treating inflammation by blocking interleukin-1 in humans,” Seminars in Immunology, vol. 25, no. 6, pp. 469–484, 2013. View at Publisher · View at Google Scholar · View at Scopus
  207. P. Vasileiou, C. Tsioufis, G. Lazaros et al., “Interleukin-8 as a predictor of acute idiopathic pericarditis recurrences. A pilot study,” International Journal of Cardiology, vol. 172, no. 3, pp. e463–e464, 2014. View at Publisher · View at Google Scholar · View at Scopus
  208. L. Cantarini, M. Imazio, A. Brucato, O. M. Lucherini, and M. Galeazzi, “Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis,” Autoimmunity Reviews, vol. 9, no. 6, pp. 436–440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. M. Finetti, A. Insalaco, L. Cantarini et al., “Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis,” The Journal of Pediatrics, vol. 164, no. 6, pp. 1425.e1–1431.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  210. P. Picco, G. Brisca, F. Traverso, A. Loy, M. Gattorno, and A. Martini, “Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): an unrecognized autoinflammatory disease?” Arthritis & Rheumatism, vol. 60, no. 1, pp. 264–268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  211. D. Vassilopoulos, G. Lazaros, C. Tsioufis, P. Vasileiou, C. Stefanadis, and D. Pectasides, “Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra),” International Journal of Cardiology, vol. 160, no. 1, pp. 66–68, 2012. View at Publisher · View at Google Scholar · View at Scopus
  212. D. Rigante, L. Cantarini, M. Imazio et al., “Autoinflammatory diseases and cardiovascular manifestations,” Annals of Medicine, vol. 43, no. 5, pp. 341–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  213. K. M. Hull, E. Drewe, I. Aksentijevich et al., “The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder,” Medicine, vol. 81, no. 5, pp. 349–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  214. A. Simon, H. Park, R. Maddipati et al., “Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 21, pp. 9801–9806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  215. L. Cantarini, O. M. Lucherini, C. T. Baldari, F. Laghi Pasini, and M. Galeazzi, “Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome,” Clinical and Experimental Rheumatology, vol. 28, no. 3, pp. 405–407, 2010. View at Google Scholar · View at Scopus
  216. L. Cantarini, O. M. Lucherini, A. Vitale et al., “Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis,” Internal Medicine Journal, vol. 43, no. 6, pp. 725–727, 2013. View at Publisher · View at Google Scholar · View at Scopus
  217. L. Cantarini, D. Rigante, G. Merlini et al., “The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up,” Seminars in Arthritis and Rheumatism, vol. 43, no. 6, pp. 818–823, 2014. View at Publisher · View at Google Scholar · View at Scopus
  218. S. Maggiolini, G. Tiberti, L. Cantarini et al., “Large pericardial effusion in a family with recurrent pericarditis: a report of probable x-linked transmission,” Experimental and Clinical Cardiology, vol. 16, no. 2, pp. 54–56, 2011. View at Google Scholar · View at Scopus
  219. L. Cantarini, O. M. Lucherini, A. Brucato et al., “Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study,” Clinical Research in Cardiology, vol. 101, no. 7, pp. 525–531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  220. L. Cantarini, O. M. Lucherini, R. Cimaz et al., “Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 4, pp. 1051–1058, 2009. View at Google Scholar · View at Scopus
  221. L. Cantarini, G. Lopalco, C. Selmi et al., “Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis,” Autoimmunity Reviews, vol. 14, no. 2, pp. 90–97, 2014. View at Publisher · View at Google Scholar
  222. M. Camacho-Lovillo and A. Méndez-Santos, “Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra),” Pediatric Cardiology, vol. 34, no. 5, pp. 1293–1294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  223. A. Scardapane, A. Brucato, F. Chiarelli, and L. Breda, “Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis,” Pediatric Cardiology, vol. 34, no. 8, pp. 1989–1991, 2013. View at Publisher · View at Google Scholar · View at Scopus
  224. G. Lazaros, P. Vasileiou, C. Koutsianas et al., “Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases,” Annals of the Rheumatic Diseases, vol. 73, no. 12, pp. 2215–2217, 2014. View at Publisher · View at Google Scholar
  225. L. Cantarini, G. Lopalco, A. Vitale et al., “Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab,” Clinical Rheumatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  226. K. Hamzaoui, M. Hamza, and K. Ayed, “Production of TNF-α and IL-1 in active Behcet's disease,” The Journal of Rheumatology, vol. 17, no. 10, pp. 1428–1429, 1990. View at Google Scholar · View at Scopus
  227. S. Pay, H. Erdem, A. Pekel et al., “Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1β play a major role in Behçet's synovitis?” Rheumatology International, vol. 26, no. 7, pp. 608–613, 2006. View at Publisher · View at Google Scholar · View at Scopus
  228. L. Cantarini, A. Vitale, M. Borri, M. Galeazzi, and R. Franceschini, “Successful use of canakinumab in a patient with resistant Behçet's disease,” Clinical and Experimental Rheumatology, vol. 30, no. 3, supplement 72, article S115, 2012. View at Google Scholar · View at Scopus
  229. J. Karasneh, A. H. Hajeer, J. Barrett, W. E. R. Ollier, M. Thornhill, and A. Gul, “Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease,” Rheumatology, vol. 42, no. 7, pp. 860–864, 2003. View at Publisher · View at Google Scholar · View at Scopus
  230. A. Akman, N. C. Ekinci, H. Kacaroglu, U. Yavuzer, E. Alpsoy, and O. Yegin, “Relationship between periodontal findings and specific polymorphisms of interleukin-1α and -1β in Turkish patients with Behçet's disease,” Archives of Dermatological Research, vol. 300, no. 1, pp. 19–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  231. M. Castrichini, P. E. Lazzerini, A. Gamberucci et al., “The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α,” European Journal of Immunology, vol. 44, no. 1, pp. 227–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  232. L. Cantarini, A. Vitale, P. Scalini et al., “Anakinra treatment in drug-resistant Behçet's disease: a case series,” Clinical Rheumatology, 2013. View at Publisher · View at Google Scholar
  233. F. Caso, D. Rigante, A. Vitale, O. M. Lucherini, and L. Cantarini, “Efficacy of anakinra in refractory Behçet's disease sacroiliitis,” Clinical and Experimental Rheumatology, vol. 32, no. 4, supplement 84, p. S171, 2014. View at Google Scholar
  234. Y. Bilginer, N. A. Ayaz, and S. Ozen, “Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease,” Clinical Rheumatology, vol. 29, no. 2, pp. 209–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  235. C. Botsios, P. Sfriso, A. Furlan, L. Punzi, and C. A. Dinarello, “Resistant Behçet disease responsive to anakinra,” Annals of Internal Medicine, vol. 149, no. 4, pp. 284–286, 2008. View at Google Scholar · View at Scopus
  236. G. Emmi, E. Silvestri, A. M. Cameli et al., “Anakinra for resistant Behçet uveitis: why not?” Clinical and Experimental Rheumatology, vol. 31, no. 3, supplement 77, pp. S152–S153, 2013. View at Google Scholar · View at Scopus
  237. A. Vitale, D. Rigante, F. Caso et al., “Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series,” Dermatology, vol. 228, no. 3, pp. 211–214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  238. S. Ugurlu, D. Ucar, E. Seyahi, G. Hatemi, and S. Yurdakul, “Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease,” Annals of the Rheumatic Diseases, vol. 71, no. 9, pp. 1589–1591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  239. L. Cantarini, G. Lopalco, F. Caso et al., “Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease,” Autoimmunity Reviews, vol. 14, no. 1, pp. 1–9, 2015. View at Publisher · View at Google Scholar
  240. F. Caso, L. Costa, D. Rigante et al., “Biological treatments in Behçet's disease: beyond anti-TNF therapy,” Mediators of Inflammation, vol. 2014, Article ID 107421, 14 pages, 2014. View at Publisher · View at Google Scholar
  241. L. Cantarini, I. Tinazzi, P. Caramaschi, F. Bellisai, A. Brogna, and M. Galeazzi, “Safety and efficacy of etanercept in children with juvenile-onset Behcet's disease,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 551–555, 2009. View at Google Scholar · View at Scopus
  242. N. Busso and A. So, “Mechanisms of inflammation in gout,” Arthritis Research and Therapy, vol. 12, no. 2, article 206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  243. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  244. C.-J. Chen, Y. Shi, A. Hearn et al., “MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals,” The Journal of Clinical Investigation, vol. 116, no. 8, pp. 2262–2271, 2006. View at Publisher · View at Google Scholar · View at Scopus
  245. P. Pelegrin and A. Surprenant, “Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway,” The Journal of Biological Chemistry, vol. 282, no. 4, pp. 2386–2394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  246. A. M. Owyang, H. Issafras, J. Corbin et al., “XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases,” mAbs, vol. 3, no. 1, pp. 49–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  247. S. B. Gratton, K. J. Scalapino, and K. H. Fye, “Case of anakinra as a steroid-sparing agent for gout inflammation,” Arthritis Care and Research, vol. 61, no. 9, pp. 1268–1270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  248. D. McGonagle, A. L. Tan, S. Shankaranarayana, J. Madden, P. Emery, and M. F. McDermott, “Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra,” Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1683–1684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  249. D. McGonagle, A. L. Tan, J. Madden, P. Emery, and M. F. McDermott, “Successful treatment of resistant pseudogout with anakinra,” Arthritis and Rheumatism, vol. 58, no. 2, pp. 631–633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  250. D. Singh and K. K. Huston, “IL-1 inhibition with anakinra in a patient with refractory gout,” Journal of Clinical Rheumatology, vol. 15, no. 7, p. 366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  251. A. So, T. de Smedt, S. Revaz, and J. Tschopp, “A pilot study of IL-1 inhibition by anakinra in acute gout,” Arthritis Research and Therapy, vol. 9, article R28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  252. N. Announ, G. Palmer, P. A. Guerne, and C. Gabay, “Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure,” Joint Bone Spine, vol. 76, no. 4, pp. 424–426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  253. A. Vitale, L. Cantarini, D. Rigante, M. Bardelli, and M. Galeazzi, “Anakinra treatment in patients with gout and type 2 diabetes,” Clinical Rheumatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  254. A. So, M. de Meulemeester, A. Pikhlak et al., “Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study,” Arthritis & Rheumatism, vol. 62, no. 10, pp. 3064–3076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  255. N. Schlesinger, M. de Meulemeester, A. Pikhlak et al., “Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study,” Arthritis Research and Therapy, vol. 13, no. 2, article R53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  256. N. Schlesinger, E. Mysler, H.-Y. Lin et al., “Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study,” Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1264–1271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  257. N. Schlesinger, R. E. Alten, T. Bardin et al., “Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions,” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1839–1848, 2012. View at Publisher · View at Google Scholar · View at Scopus
  258. E. Mitha, H. R. Schumacher, L. Fouche et al., “Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial,” Rheumatology, vol. 52, no. 7, pp. 1285–1292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  259. H. R. Schumacher Jr., R. R. Evans, K. G. Saag et al., “Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study,” Arthritis Care and Research, vol. 64, no. 10, pp. 1462–1470, 2012. View at Publisher · View at Google Scholar · View at Scopus
  260. R. A. Terkeltaub, H. R. Schumacher, J. D. Carter et al., “Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator,” Arthritis Research & Therapy, vol. 15, no. 1, article R25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  261. R. Terkeltaub, J. S. Sundy, H. R. Schumacher et al., “The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1613–1617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  262. A. Solomon, D. Dursun, Z. Liu, Y. Xie, A. Macri, and S. C. Pflugfelder, “Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease,” Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2283–2292, 2001. View at Google Scholar · View at Scopus
  263. M. Azuma, K. Motegi, K. Aota, Y. Hayashi, and M. Sato, “Role of cytokines in the destruction of acinar structure in Sjögren's syndrome salivary glands,” Laboratory Investigation, vol. 77, no. 3, pp. 269–280, 1997. View at Google Scholar · View at Scopus
  264. P. Willeke, H. Schotte, B. Schlüter et al., “Interleukin 1beta and tumour necrosis factor α secreting cells are increased in the peripheral blood of patients with primary Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 62, no. 4, pp. 359–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  265. R. I. Fox, H.-I. Kang, D. Ando, J. Abrams, and E. Pisa, “Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome,” The Journal of Immunology, vol. 152, no. 11, pp. 5532–5539, 1994. View at Google Scholar · View at Scopus
  266. J.-J. Dubost, S. Perrier, M. Afane et al., “IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjogren's syndrome (SS),” Clinical and Experimental Immunology, vol. 106, no. 2, pp. 237–242, 1996. View at Publisher · View at Google Scholar · View at Scopus
  267. Y.-T. Chen, S. Lazarev, A. F. Bahrami et al., “Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjögren's syndrome,” Laboratory Investigation, vol. 92, no. 4, pp. 556–570, 2012. View at Publisher · View at Google Scholar · View at Scopus
  268. Y. Muraki, A. Tsutsumi, R. Takahashi et al., “Polymorphisms of IL-1β gene in Japanese patients with Sjogren's syndrome and systemic lupus erythematosus,” The Journal of Rheumatology, vol. 31, no. 4, pp. 720–725, 2004. View at Google Scholar · View at Scopus
  269. S. Hurst and S. M. Collins, “Interleukin-1β modulation of norepinephrine release from rat myenteric nerves,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 264, no. 1, pp. G30–G35, 1993. View at Google Scholar · View at Scopus
  270. C. A. Murray, B. McGahon, S. McBennett, and M. A. Lynch, “Interleukin-1β inhibits glutamate release in hippocampus of young, but not aged, rats,” Neurobiology of Aging, vol. 18, no. 3, pp. 343–348, 1997. View at Publisher · View at Google Scholar · View at Scopus
  271. D. Zoukhri, R. R. Hodges, D. Byon, and C. L. Kublin, “Role, of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia,” Investigative Ophthalmology and Visual Science, vol. 43, no. 5, pp. 1429–1436, 2002. View at Google Scholar · View at Scopus
  272. M. Bulosan, K. M. Pauley, K. Yo et al., “Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset,” Immunology and Cell Biology, vol. 87, no. 1, pp. 81–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  273. S. Eltom, C. S. Stevenson, J. Rastrick et al., “P2x7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke,” PLoS ONE, vol. 6, no. 9, Article ID e24097, 2011. View at Publisher · View at Google Scholar · View at Scopus
  274. H. J. Anders and D. A. Muruve, “The inflammasomes in kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1007–1018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  275. B. Vandanmagsar, Y. H. Youm, A. Ravussin et al., “The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,” Nature Medicine, vol. 17, no. 2, pp. 179–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  276. A. Yamada, R. Arakaki, Y. Kudo, and N. Ishimaru, “Targeting IL-1 in Sjögren's syndrome,” Expert Opinion on Therapeutic Targets, vol. 17, no. 4, pp. 393–401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  277. K. B. Norheim, E. Harboe, L. G. Gøransson, and R. Omdal, “Interleukin-1 inhibition and fatigue in primary sjögren's syndrome—a double blind, randomised clinical trial,” PLoS ONE, vol. 7, no. 1, Article ID e30123, 2012. View at Publisher · View at Google Scholar · View at Scopus
  278. F. Amparo, M. H. Dastjerdi, A. Okanobo et al., “Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial,” JAMA Ophthalmology, vol. 131, no. 6, pp. 715–723, 2013. View at Publisher · View at Google Scholar · View at Scopus
  279. T. E. King Jr., “Clinical advances in the diagnosis and therapy of the interstitial lung diseases,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 3, pp. 268–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  280. G. A. Koretzky, J. A. Elias, S. L. Kay, M. D. Rossman, P. C. Nowell, and R. P. Daniele, “Spontaneous production of interleukin-1 by human alveolar macrophages,” Clinical Immunology and Immunopathology, vol. 29, no. 3, pp. 443–450, 1983. View at Publisher · View at Google Scholar · View at Scopus
  281. S. Nagai, M. Takeuchi, K. Watanabe, H. Aung, and T. Izumi, “Smoking and interleukin-1 activity released from human alveolar macrophages in healthy subjects,” Chest, vol. 94, no. 4, pp. 694–700, 1988. View at Publisher · View at Google Scholar · View at Scopus
  282. M. Takeuchi, S. Nagai, H. Nakada et al., “Characterization of IL-1 inhibitory factor released from human alveolar macrophages as IL-1 receptor antagonist,” Clinical and Experimental Immunology, vol. 88, no. 1, pp. 181–187, 1992. View at Google Scholar · View at Scopus
  283. C. A. Dinarello, “Interleukin-1,” Cytokine and Growth Factor Reviews, vol. 8, no. 4, pp. 253–265, 1997. View at Publisher · View at Google Scholar · View at Scopus
  284. L. H. Pan, H. Ohtani, K. Yamauchi, and H. Nagura, “Co-expression of TNFα and IL-1β in human acute pulmonary fibrotic diseases: an immunohistochemical analysis,” Pathology International, vol. 46, no. 2, pp. 91–99, 1996. View at Publisher · View at Google Scholar · View at Scopus
  285. C. J. Johnston, B. Piedboeuf, P. Rubin, J. P. Williams, R. Baggs, and J. N. Finkelstein, “Early and persistent alterations in the expression of interleukin-1α, interleukin-1β and tumor necrosis factor α mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation,” Radiation Research, vol. 145, no. 6, pp. 762–767, 1996. View at Publisher · View at Google Scholar · View at Scopus
  286. M. Kolb, P. J. Margetts, D. C. Anthony, F. Pitossi, and J. Gauldie, “Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis,” The Journal of Clinical Investigation, vol. 107, no. 12, pp. 1529–1536, 2001. View at Publisher · View at Google Scholar · View at Scopus
  287. P. J. Sime, Z. Xing, F. L. Graham, K. G. Csaky, and J. Gauldie, “Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung,” The Journal of Clinical Investigation, vol. 100, no. 4, pp. 768–776, 1997. View at Publisher · View at Google Scholar · View at Scopus
  288. P. F. Piguet, C. Vesin, G. E. Grau, and R. C. Thompson, “Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica,” Cytokine, vol. 5, no. 1, pp. 57–61, 1993. View at Publisher · View at Google Scholar · View at Scopus
  289. R. W. Wilmott, J. A. Kitzmiller, M. A. Fiedler, and J. M. Stark, “Generation of a transgenic mouse with lung-specific overexpression of the human interleukin-1 receptor antagonist protein,” American Journal of Respiratory Cell and Molecular Biology, vol. 18, no. 3, pp. 429–434, 1998. View at Publisher · View at Google Scholar · View at Scopus
  290. N. P. Barlo, C. H. M. van Moorsel, N. M. Korthagen et al., “Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis,” Clinical and Experimental Immunology, vol. 166, no. 3, pp. 346–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  291. S. Reddy, S. Jia, R. Geoffrey et al., “An autoinflammatory disease due to homozygous deletion of the IL1RN locus,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2438–2444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  292. S. L. Cassel, S. C. Eisenbarth, S. S. Iyer et al., “The Nalp3 inflammasome is essential for the development of silicosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9035–9040, 2008. View at Publisher · View at Google Scholar · View at Scopus
  293. C. M. Artlett, S. Sassi-Gaha, J. L. Rieger, A. C. Boesteanu, C. A. Feghali-Bostwick, and P. D. Katsikis, “The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis,” Arthritis & Rheumatism, vol. 63, no. 11, pp. 3563–3574, 2011. View at Publisher · View at Google Scholar · View at Scopus
  294. A. Furlan, C. Botsios, A. Ruffatti, S. Todesco, and L. Punzi, “Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report,” Joint Bone Spine, vol. 75, no. 3, pp. 366–367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  295. S. M. Keidel, R. K. Hoyles, and N. M. R. Wilkinson, “Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra,” Rheumatology, vol. 53, no. 3, Article ID ket211, pp. 573–574, 2014. View at Publisher · View at Google Scholar · View at Scopus
  296. A. Kontzias and P. Efthimiou, “Adult-onset still's disease: pathogenesis, clinical manifestations and therapeutic advances,” Drugs, vol. 68, no. 3, pp. 319–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  297. J.-H. Choi, C.-H. Suh, Y.-M. Lee et al., “Serum cytokine profiles in patients with adult onset Still's disease,” Journal of Rheumatology, vol. 30, no. 11, pp. 2422–2427, 2003. View at Google Scholar · View at Scopus
  298. D.-Y. Chen, J.-L. Lan, F.-J. Lin, and T.-Y. Hsieh, “Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still's disease,” The Journal of Rheumatology, vol. 31, no. 11, pp. 2189–2198, 2004. View at Google Scholar · View at Scopus
  299. A. Stabile, B. Bertoni, V. Ansuini, I. la Torraca, A. Sallì, and D. Rigante, “The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age,” European Review for Medical and Pharmacological Sciences, vol. 10, no. 2, pp. 53–59, 2006. View at Google Scholar · View at Scopus
  300. V. Pascual, F. Allantaz, E. Arce, M. Punaro, and J. Banchereau, “Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade,” The Journal of Experimental Medicine, vol. 201, no. 9, pp. 1479–1486, 2005. View at Publisher · View at Google Scholar · View at Scopus
  301. L. Naumann, E. Feist, A. Natusch et al., “IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 466–467, 2010. View at Publisher · View at Google Scholar · View at Scopus
  302. T. Lequerré, P. Quartier, D. Rosellini et al., “Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 302–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  303. I. Kötter, A. Wacker, S. Koch et al., “Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature,” Seminars in Arthritis and Rheumatism, vol. 37, no. 3, pp. 189–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  304. G. D. Kalliolias, P. E. Georgiou, I. A. Antonopoulos, A. P. Andonopoulos, and S.-N. C. Liossis, “Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial,” Annals of the Rheumatic Diseases, vol. 66, no. 6, pp. 842–843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  305. A. A. Fitzgerald, S. A. LeClercq, A. Yan, J. E. Homik, and C. A. Dinarello, “Rapid responses to anakinra in patients with refractory adult-onset Still's disease,” Arthritis and Rheumatism, vol. 52, no. 6, pp. 1794–1803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  306. J. A. Aelion and S. K. Odhav, “Prompt response to treatment with anakinra in adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 63, supplement 1, p. 265, 2004. View at Google Scholar
  307. B. Haraoui, D. Bourrelle, and E. Kaminska, “Anakinra in the treatment of adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 63, supplement 1, article 263, 2004. View at Google Scholar
  308. M. Lahiri and G.-G. Teng, “A case of refractory adult-onset Still's disease treated with anakinra,” International Journal of Rheumatic Diseases, vol. 13, no. 3, pp. e36–e41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  309. G. Moulis, L. Sailler, L. Astudillo, G. Pugnet, and P. Arlet, “May anakinra be used earlier in adult onset Still disease?” Clinical Rheumatology, vol. 29, no. 10, pp. 1199–1200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  310. E. Mylona, S. Golfinopoulou, M. Samarkos, P. Fanourgiakis, V. Papadakos, and A. Skoutelis, “Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra,” Clinical Rheumatology, vol. 27, no. 5, pp. 659–661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  311. B. Raffeiner, C. Botsios, C. A. Dinarello, F. Ometto, L. Punzi, and R. Ramonda, “Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra,” Joint Bone Spine, vol. 78, no. 1, pp. 100–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  312. A. Rudinskaya and D. H. Trock, “Successful treatment of a patient with refractory Adult-onset Still disease with anakinra,” Journal of Clinical Rheumatology, vol. 9, no. 5, pp. 330–332, 2003. View at Publisher · View at Google Scholar · View at Scopus
  313. H. Tamaki, H. Shimizu, E. Hiraoka et al., “Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease,” Modern Rheumatology, vol. 20, no. 2, pp. 200–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  314. F. M. Vasques Godinho, M. J. Parreira Santos, and J. C. da Silva, “Refractory adult onset Still's disease successfully treated with anakinra,” Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 647–648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  315. S. Vordenbäumen, B. Ostendorf, O. Sander, J. Richter, and M. Schneider, “Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease,” Annals of the Rheumatic Diseases, vol. 68, no. 3, pp. 450–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  316. J. Youssef, E. Lazaro, P. Blanco, and J. F. Viallard, “Blockade of interleukin 1 receptor in still's disease affects activation of peripheral T-lymphocytes,” Journal of Rheumatology, vol. 35, no. 12, pp. 2453–2456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  317. P. Woo, “Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 281–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  318. Á. Terán, F. Casafont, E. Fábrega, V. M. Martínez-Taboada, V. Rodríguez-Valverde, and F. Pons-Romero, “Adult-onset Still's disease with liver failure requiring liver transplantation,” Gastroenterología y Hepatología, vol. 32, no. 10, pp. 681–686, 2009. View at Publisher · View at Google Scholar · View at Scopus
  319. C. Rinkin, C. van Durme, B. Fautrel, and M. Malaise, “A rare case of arthritis and fever,” Revue Medicale de Liege, vol. 68, no. 7-8, pp. 423–427, 2013. View at Google Scholar · View at Scopus
  320. C. Iliou, C. Papagoras, N. Tsifetaki, P. V. Voulgari, and A. A. Drosos, “Adult-onset Still's disease: clinical, serological and therapeutic considerations,” Clinical and Experimental Rheumatology, vol. 31, no. 1, pp. 47–52, 2013. View at Google Scholar · View at Scopus
  321. N. T. Jaqua, D. Finger, and J. S. Hawley, “Adult-onset Still's disease masquerading as sepsis in an asplenic active duty soldier,” Case Reports in Medicine, vol. 2012, Article ID 349521, 3 pages, 2012. View at Publisher · View at Google Scholar
  322. K. Laskari, A. G. Tzioufas, and H. M. Moutsopoulos, “Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study,” Arthritis Research and Therapy, vol. 13, no. 3, article R91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  323. D. Nordström, A. Knight, R. Luukkainen et al., “Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study,” The Journal of Rheumatology, vol. 39, no. 10, pp. 2008–2011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  324. C. Giampietro, M. Ridene, T. Lequerre et al., “Anakinra in adult-onset still's disease: long-term treatment in patients resistant to conventional therapy,” Arthritis Care and Research, vol. 65, no. 5, pp. 822–826, 2013. View at Publisher · View at Google Scholar · View at Scopus
  325. C. Henderson, W. Mildred, T.-H. Pham et al., “Safety and efficacy of IL-1 Trap in resistant adult onset Still's disease: 24 month follow-up of open label treatment and biomarkers of response,” Arthritis & Rheumatology, vol. 62, supplement 10, p. 1831, 2010. View at Google Scholar
  326. O. Petryna, J. J. Cush, and P. Efthimiou, “IL-1 trap rilonacept in refractory adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 71, no. 12, pp. 2056–2057, 2012. View at Publisher · View at Google Scholar · View at Scopus
  327. A. Kontzias and P. Efthimiou, “The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease,” Seminars in Arthritis and Rheumatism, vol. 42, no. 2, pp. 201–205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  328. A. Lo Gullo, A. Caruso, N. Pipitone, P. Macchioni, G. Pazzola, and C. Salvarani, “Canakinumab in a case of adult onset Still's disease: efficacy only on systemic manifestations,” Joint Bone Spine, vol. 81, no. 4, pp. 376–377, 2014. View at Publisher · View at Google Scholar · View at Scopus